Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in China Grant

This study, supported by Pfizer, aims to evaluate the long-term effectiveness of Ritlecitinib in treating adult and adolescent patients with severe alopecia areata in China. It encourages the development of real-world studies to assess treatment outcomes over 12 months, examining various treatment patterns and efficacy targets. The total project duration is set for 18 months, aligning with Pfizer's commitment to improving patient outcomes in areas of unmet medical need.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in China
Overview
This competitive program aims to estimate long-term effectiveness of Ritlecitinib for adult and adolescent patients with severe alopecia areata (AA). Research projects to be supported should be focused on the effectiveness of Ritlecitinib in real-world clinical settings in China.
Project Types and Area of Interest
Potential applicants are encouraged to develop prospective or retrospective real-world studies of adult and adolescent severe AA patients treated with Ritlecitinib in real-world practices in China. This may include:
The long-term effectiveness of Ritlecitinib treatment (12 months follow-up) for adult and adolescent with severe AA patients. The total project duration is 18 months.Different treatment patterns can be investigated.Explore the treatment target of AA, and the efficacy under these targets.